Aldeyra reports positive Phase 2 data for ADX-2191 in retinitis pigmentosa

Aldeyra Therapeutics, Inc.

Statistically significant improvement in best corrected visual acuity (P<0.0001) and low-light visual acuity (P=0.0001).
Perimetry showed improved macular sensitivity (P<0.0001) and dark-adapted peripheral sensitivity (P<0.0001).
Electroretinography time to response improved (P=0.02); no safety concerns identified.
All 8 patients completed trial; ADX-2191 well tolerated with no serious adverse events.
Company plans to discuss Phase 2/3 trial design with regulatory authorities.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.